IDEX Biometrics ASA (IDXAF) Stock
Headquartered in Oslo, Norway, and established in 1996, IDEX Biometrics ASA is dedicated to developing and commercializing fingerprint authentication technology. The company's innovative biometric solutions are deployed globally, spanning markets in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About IDEX Biometrics ASA
Headquartered in Oslo, Norway, and established in 1996, IDEX Biometrics ASA is dedicated to developing and commercializing fingerprint authentication technology. The company's innovative biometric solutions are deployed globally, spanning markets in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. These cutting-edge systems are primarily utilized in contactless financial payment applications, secure access control, and various smart cards, including specialized card-based hardware for safeguarding digital currencies. IDEX Biometrics ASA predominantly caters to smart card manufacturers focused on financial payment systems and the burgeoning biometric payment card industry.
IDEX Biometrics ASA is headquartered in NO.
IDEX Biometrics ASA (IDXAF) stock trades at $0.89 with a market capitalization of $68.80M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.96, reflecting a net loss over the last twelve months, a negative price-to-book of -89.13, reflecting negative shareholders' equity, price-to-sales of 194.32. Over the past 52 weeks the stock has ranged between $0.03 and $0.89, and currently trades at or near its 52-week high.
On profitability, IDEX Biometrics ASA generates a return on equity (ROE) of -889.59% (not meaningful, as shareholders' equity is negative), return on capital employed of -275.00%, an operating margin of -1394.84%.
Official website: www.idexbiometrics.com
Related Technology Stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.